Loading clinical trials...
Loading clinical trials...
A Study Investigating Safety, Tolerability and Efficacy of UBT251 in Participants Living With Overweight or Obesity
Conditions
Interventions
UBT251
Placebo
Locations
3
United States
Altasciences Clinical LA, Inc.
Cypress, California, United States
Altasciences Clinical Kansas, Inc.
Overland Park, Kansas, United States
Altasciences Clinical Company, Inc
Montreal, Quebec, Canada
Start Date
February 2, 2026
Primary Completion Date
January 14, 2027
Completion Date
February 18, 2027
Last Updated
April 21, 2026
NCT07037459
NCT07351045
NCT07244458
NCT07508241
NCT07311850
NCT05746039
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions